We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
sFlt-1/PlGF ratio test for pre-eclampsia: an economic assessment for the UK.
- Authors
Vatish, M.; Strunz‐McKendry, T.; Hund, M.; Allegranza, D.; Wolf, C.; Smare, C.
- Abstract
<bold>Objectives: </bold>To assess the economic impact of introducing into clinical practice in the UK the soluble fms-like tyrosine kinase (sFlt-1) to placental growth factor (PlGF) ratio test for guiding the management of pre-eclampsia.<bold>Methods: </bold>We used an economic model estimating the incremental value of information, from a UK National Health Service payer's perspective, generated by the sFlt-1/PlGF ratio test, compared with current diagnostic procedures, in guiding the management of women with suspected pre-eclampsia. The economic model estimated costs associated with the diagnosis and management of pre-eclampsia in pregnant women between 24 + 0 and 36 + 6 weeks' gestation, managed in either a 'test' scenario in which the sFlt-1/PlGF test is used in addition to current diagnostic procedures, or a 'no-test' scenario in which clinical decisions are based on current diagnostic procedures alone. Test characteristics and resource use were derived from PROGNOSIS, a non-interventional study in women presenting with clinical suspicion of pre-eclampsia. The main outcome measure from the economic model was the cost per patient per episode of care, from first suspicion of pre-eclampsia to birth.<bold>Results: </bold>Introduction of the sFlt-1/PlGF ratio test into clinical practice is expected to result in cost savings of £344 per patient compared with a no-test scenario. Savings are generated primarily through an improvement in diagnostic accuracy and subsequent reduction in unnecessary hospitalization.<bold>Conclusions: </bold>Introducing the sFlt-1/PlGF ratio test into clinical practice in the UK was shown to be cost-saving by reducing unnecessary hospitalization of women at low risk of developing pre-eclampsia. In addition, the test ensures that those women at higher risk are identified and managed appropriately. © 2016 Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
- Subjects
CLINICAL medicine; PROTEIN-tyrosine kinases; GREAT Britain. National Health Service; PREECLAMPSIA; GESTATIONAL age; HOSPITAL care; PREECLAMPSIA diagnosis; CELL receptors; COST effectiveness; LONGITUDINAL method; MEMBRANE proteins; STATISTICAL models
- Publication
Ultrasound in Obstetrics & Gynecology, 2016, Vol 48, Issue 6, p765
- ISSN
0960-7692
- Publication type
journal article
- DOI
10.1002/uog.15997